Cargando…
Different levels of serum microRNAs in prostate cancer and benign prostatic hyperplasia: evaluation of potential diagnostic and prognostic role
INTRODUCTION: Diagnosis of prostate cancer (PCa) is based on prostate biopsy that is performed when prostate specific antigen (PSA) is persistently altered over time and/or abnormal digital rectal examination is found. Serum PSA levels increase in both PCa and benign prostatic hyperplasia, leading t...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5167485/ https://www.ncbi.nlm.nih.gov/pubmed/28008272 http://dx.doi.org/10.2147/OTT.S119027 |
_version_ | 1782483185010999296 |
---|---|
author | Cochetti, Giovanni Poli, Giulia Guelfi, Gabriella Boni, Andrea Egidi, Maria Giulia Mearini, Ettore |
author_facet | Cochetti, Giovanni Poli, Giulia Guelfi, Gabriella Boni, Andrea Egidi, Maria Giulia Mearini, Ettore |
author_sort | Cochetti, Giovanni |
collection | PubMed |
description | INTRODUCTION: Diagnosis of prostate cancer (PCa) is based on prostate biopsy that is performed when prostate specific antigen (PSA) is persistently altered over time and/or abnormal digital rectal examination is found. Serum PSA levels increase in both PCa and benign prostatic hyperplasia, leading to an increased number of unnecessary biopsies. There is an urgent need to unravel PCa-specific molecular signatures. PATIENTS AND METHODS: This study aimed at characterizing a panel of circulating micro RNAs (miRNAs) that could distinguish PCa from benign prostatic hyperplasia in a population of age-matched patients with increased PSA levels. Both miRNAs targeting genes involved in PCa onset and miRNAs whose role in PCa has been highlighted in other studies were included. For this purpose, let-7c, let-7e, let-7i, miR-26a-5p, miR-26b-5p, miR-24-3p, miR-23b-3p, miR-27-b-3p, miR-106a-5p, miR-20b-5p, miR-18b-5p, miR-19b-2-5p, miR-363-3p, miR-497, miR-195, miR-25-3p, miR-30c-5p, miR-622, miR-874-3p, miR-346 and miR-940 were assayed through real-time PCR in 64 patients with PCa and compared with 60 patients with benign prostatic hyperplasia. The ability of miRNAs to predict the stage of disease was also analyzed. RESULTS: Let-7c, let-7e, let-7i, miR-26a-5p, miR-26b-5p, miR-18b-5p and miR-25-3p were able to discriminate patients with PCa from those harboring benign prostatic hyperplasia, both presenting altered PSA levels (>3 ng/mL). MiR-25-3p and miR-18b-5p showed the highest sensitivity and specificity to predict PCa, respectively. The combination of these two miRNAs improved the overall sensitivity. A correlation between pathological Gleason score and miRNA expression levels was reported; miR-363-3p, miR-26a-5p, miR-26b-5p, miR-106a-5p, miR-18b-5p, miR-25-3p and let-7i decreased in expression concomitantly with an increase in malignancy. CONCLUSION: This study confirms serum miRNAs to be reliable candidates for the development of minimally invasive biomarkers for the diagnosis and prognosis of PCa, particularly in those cases where PSA acts as a flawed marker. |
format | Online Article Text |
id | pubmed-5167485 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-51674852016-12-22 Different levels of serum microRNAs in prostate cancer and benign prostatic hyperplasia: evaluation of potential diagnostic and prognostic role Cochetti, Giovanni Poli, Giulia Guelfi, Gabriella Boni, Andrea Egidi, Maria Giulia Mearini, Ettore Onco Targets Ther Original Research INTRODUCTION: Diagnosis of prostate cancer (PCa) is based on prostate biopsy that is performed when prostate specific antigen (PSA) is persistently altered over time and/or abnormal digital rectal examination is found. Serum PSA levels increase in both PCa and benign prostatic hyperplasia, leading to an increased number of unnecessary biopsies. There is an urgent need to unravel PCa-specific molecular signatures. PATIENTS AND METHODS: This study aimed at characterizing a panel of circulating micro RNAs (miRNAs) that could distinguish PCa from benign prostatic hyperplasia in a population of age-matched patients with increased PSA levels. Both miRNAs targeting genes involved in PCa onset and miRNAs whose role in PCa has been highlighted in other studies were included. For this purpose, let-7c, let-7e, let-7i, miR-26a-5p, miR-26b-5p, miR-24-3p, miR-23b-3p, miR-27-b-3p, miR-106a-5p, miR-20b-5p, miR-18b-5p, miR-19b-2-5p, miR-363-3p, miR-497, miR-195, miR-25-3p, miR-30c-5p, miR-622, miR-874-3p, miR-346 and miR-940 were assayed through real-time PCR in 64 patients with PCa and compared with 60 patients with benign prostatic hyperplasia. The ability of miRNAs to predict the stage of disease was also analyzed. RESULTS: Let-7c, let-7e, let-7i, miR-26a-5p, miR-26b-5p, miR-18b-5p and miR-25-3p were able to discriminate patients with PCa from those harboring benign prostatic hyperplasia, both presenting altered PSA levels (>3 ng/mL). MiR-25-3p and miR-18b-5p showed the highest sensitivity and specificity to predict PCa, respectively. The combination of these two miRNAs improved the overall sensitivity. A correlation between pathological Gleason score and miRNA expression levels was reported; miR-363-3p, miR-26a-5p, miR-26b-5p, miR-106a-5p, miR-18b-5p, miR-25-3p and let-7i decreased in expression concomitantly with an increase in malignancy. CONCLUSION: This study confirms serum miRNAs to be reliable candidates for the development of minimally invasive biomarkers for the diagnosis and prognosis of PCa, particularly in those cases where PSA acts as a flawed marker. Dove Medical Press 2016-12-13 /pmc/articles/PMC5167485/ /pubmed/28008272 http://dx.doi.org/10.2147/OTT.S119027 Text en © 2016 Cochetti et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Cochetti, Giovanni Poli, Giulia Guelfi, Gabriella Boni, Andrea Egidi, Maria Giulia Mearini, Ettore Different levels of serum microRNAs in prostate cancer and benign prostatic hyperplasia: evaluation of potential diagnostic and prognostic role |
title | Different levels of serum microRNAs in prostate cancer and benign prostatic hyperplasia: evaluation of potential diagnostic and prognostic role |
title_full | Different levels of serum microRNAs in prostate cancer and benign prostatic hyperplasia: evaluation of potential diagnostic and prognostic role |
title_fullStr | Different levels of serum microRNAs in prostate cancer and benign prostatic hyperplasia: evaluation of potential diagnostic and prognostic role |
title_full_unstemmed | Different levels of serum microRNAs in prostate cancer and benign prostatic hyperplasia: evaluation of potential diagnostic and prognostic role |
title_short | Different levels of serum microRNAs in prostate cancer and benign prostatic hyperplasia: evaluation of potential diagnostic and prognostic role |
title_sort | different levels of serum micrornas in prostate cancer and benign prostatic hyperplasia: evaluation of potential diagnostic and prognostic role |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5167485/ https://www.ncbi.nlm.nih.gov/pubmed/28008272 http://dx.doi.org/10.2147/OTT.S119027 |
work_keys_str_mv | AT cochettigiovanni differentlevelsofserummicrornasinprostatecancerandbenignprostatichyperplasiaevaluationofpotentialdiagnosticandprognosticrole AT poligiulia differentlevelsofserummicrornasinprostatecancerandbenignprostatichyperplasiaevaluationofpotentialdiagnosticandprognosticrole AT guelfigabriella differentlevelsofserummicrornasinprostatecancerandbenignprostatichyperplasiaevaluationofpotentialdiagnosticandprognosticrole AT boniandrea differentlevelsofserummicrornasinprostatecancerandbenignprostatichyperplasiaevaluationofpotentialdiagnosticandprognosticrole AT egidimariagiulia differentlevelsofserummicrornasinprostatecancerandbenignprostatichyperplasiaevaluationofpotentialdiagnosticandprognosticrole AT meariniettore differentlevelsofserummicrornasinprostatecancerandbenignprostatichyperplasiaevaluationofpotentialdiagnosticandprognosticrole |